Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

17.31 +0.04 (+0.23%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

18 19 Next >

Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday ↗

September 09, 2024

Via Benzinga

Starbucks To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Monday ↗

September 09, 2024

Via Benzinga

Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda ↗

September 09, 2024

Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda. The biotech stock rallied 30%.

Via Investor's Business Daily

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half ↗

September 09, 2024

Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free survival compared to Merck's Keytruda in non-small cell lung cancer patients,...

Via Benzinga

Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

September 09, 2024

Via Benzinga

Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China

September 08, 2024

From Summit Therapeutics Inc.

Via Business Wire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 06, 2024

From Summit Therapeutics Inc.

Via Business Wire

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024

August 12, 2024

From Summit Therapeutics Inc.

Via Business Wire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 09, 2024

From Summit Therapeutics Inc.

Via Business Wire

SMMT Stock Earnings: Summit Therapeutics Beats EPS for Q2 2024 ↗

August 06, 2024

SMMT stock results show that Summit Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024

August 06, 2024

From Summit Therapeutics Inc.

Via Business Wire

Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024

July 29, 2024

From Summit Therapeutics Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

July 26, 2024

Via Benzinga

Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab

July 25, 2024

From Summit Therapeutics Inc.

Via Business Wire

Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs ↗

July 23, 2024

What sectors outperformed after Trump won the 2016 election, and which outperformed during his term?

Via Investor's Business Daily

Topics Government

IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday ↗

July 22, 2024

Via Benzinga

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details ↗

July 14, 2024

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Via Benzinga

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 03, 2024

From Summit Therapeutics Inc.

Via Business Wire

7 Top Stocks Under $10: June 2024 Edition ↗

June 24, 2024

While blue-chip stocks are great, it's also a good idea to invest in top stocks under $10 to help improve your portfolio's diversification.

Via InvestorPlace

3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street ↗

June 17, 2024

These high-flying stocks could have more room to run if analysts are right.

Via The Motley Fool

Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million ↗

June 08, 2024

Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...

Via Talk Markets

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 07, 2024

Via Benzinga

Five Below Posts Weak Q1 Results, Joins Sprinklr, Dorian LPG And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 06, 2024

Via Benzinga

Why Summit Therapeutics Stock Is Trading 8% Higher Monday ↗

June 03, 2024

Based on data from a Phase III HARMONi-A clinical trial, sponsored by Akeso, that showed promising results for treating certain cancers, China granted Summit the marketing authorization.

Via Benzinga

Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗

June 03, 2024

Via Benzinga

Summit Raises $200 Million; Also Expands License Territories for Ivonescimab

June 03, 2024

From Summit Therapeutics Inc.

Via Business Wire

Day Trading During A Slow Holiday Week ↗

June 01, 2024

We made it to the end of a holiday-shortened week. It was a slow week of day trading, but I’m happy with how it finished. Let’s break it down in today’s recap.

Via Talk Markets

Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership ↗

June 01, 2024

Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in...

Via Talk Markets

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA

June 01, 2024

From Summit Therapeutics Inc.

Via Business Wire

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

May 31, 2024

From Summit Therapeutics Inc.

Via Business Wire

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.